Belgian value-added medicines company Hyloris Pharmaceuticals SA has outlined an ambitious growth strategy while announcing its financial and operational results for the full-year ending 31 December 2021. Its plans will be supported by its €50m ($55.4m) in cash and cash equivalents as of the end of the year.
Hyloris Outlines Ambitious Growth Strategy During Full-Year Results
Belgian Value-Added Medicines Specialist Wraps Up A Successful Year In Business
Hyloris expects to expand its portfolio to around 30 candidates by 2024, bolstered by €50m in cash and cash equivalents as of the end of 2021.
